Question normal

First, thank you to the authors for a well-done study. I'm curious about the logic as to why OS was the primary endpoint? Though clinically meaningful, sedation is not targeted to address the underlying pathologic process and therefore I think would be unlikely to offer benefit above other sedative agents in terms of survivability. Also, the FDA label shows precedex is approved for <24 hours of use. Though I have seen it used longer in clinical practice, were patients who developed adverse events of bradycardia/hypotension receiving greater cumulative doses or longer durations of therapy (ie greater than the median dose duration)?